[go: up one dir, main page]

PT2260850T - Antagonistas do recetor de a2a para utilização no tratamento de distúrbios de movimento - Google Patents

Antagonistas do recetor de a2a para utilização no tratamento de distúrbios de movimento

Info

Publication number
PT2260850T
PT2260850T PT10179406T PT10179406T PT2260850T PT 2260850 T PT2260850 T PT 2260850T PT 10179406 T PT10179406 T PT 10179406T PT 10179406 T PT10179406 T PT 10179406T PT 2260850 T PT2260850 T PT 2260850T
Authority
PT
Portugal
Prior art keywords
treatment
receptor antagonists
movement disorders
disorders
movement
Prior art date
Application number
PT10179406T
Other languages
English (en)
Inventor
Kase Hiroshi
Karasawa Akira
Mori Akihisa
Waki Yutaka
Ohsawa Yutaka
Kuwana Yoshihisa
Original Assignee
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27663091&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2260850(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kogyo Kk
Publication of PT2260850T publication Critical patent/PT2260850T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT10179406T 2002-01-28 2003-01-28 Antagonistas do recetor de a2a para utilização no tratamento de distúrbios de movimento PT2260850T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35241302P 2002-01-28 2002-01-28

Publications (1)

Publication Number Publication Date
PT2260850T true PT2260850T (pt) 2018-10-24

Family

ID=27663091

Family Applications (2)

Application Number Title Priority Date Filing Date
PT15165962T PT2942082T (pt) 2002-01-28 2003-01-28 Antagonistas do recetor de a2a para utilização no tratamento de distúrbios de movimento
PT10179406T PT2260850T (pt) 2002-01-28 2003-01-28 Antagonistas do recetor de a2a para utilização no tratamento de distúrbios de movimento

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT15165962T PT2942082T (pt) 2002-01-28 2003-01-28 Antagonistas do recetor de a2a para utilização no tratamento de distúrbios de movimento

Country Status (16)

Country Link
US (7) US20040198753A1 (pt)
EP (4) EP2260850B1 (pt)
JP (3) JP4376630B2 (pt)
KR (5) KR20120103740A (pt)
CN (3) CN1646132A (pt)
AU (2) AU2003207734C1 (pt)
BR (1) BR0306919A (pt)
CA (2) CA2473864C (pt)
CO (1) CO5601022A2 (pt)
EA (1) EA200400982A1 (pt)
ES (2) ES2716404T3 (pt)
HU (2) HUE043353T2 (pt)
MX (1) MXPA04007299A (pt)
PT (2) PT2942082T (pt)
TR (1) TR201903603T4 (pt)
WO (1) WO2003063876A2 (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2348371B (en) * 2000-03-14 2001-04-04 Soares Da Silva Patricio Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
ES2716404T3 (es) * 2002-01-28 2019-06-12 Kyowa Hakko Kogyo Kk Antagonistas de receptores A2A para su uso en el tratamiento de trastornos del movimiento
EA008339B1 (ru) † 2002-08-30 2007-04-27 Киова Хакко Когио Ко., Лтд. Способы лечения пациентов, страдающих синдромом усталых ног или связанными с ним заболеваниями
TWI331036B (en) * 2002-12-19 2010-10-01 Schering Corp Adenosine a2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
US20060106040A1 (en) * 2002-12-19 2006-05-18 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
US20060128694A1 (en) * 2002-12-19 2006-06-15 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
AR056615A1 (es) * 2002-12-27 2007-10-17 Kyowa Hakko Kogyo Kk Un metodo de tratamiento de trastornos de la conducta
TW200507850A (en) * 2003-07-25 2005-03-01 Kyowa Hakko Kogyo Kk Pharmaceutical composition
DE10361258A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
US20050197385A1 (en) * 2004-02-20 2005-09-08 Schwarz Pharma Ag Use of rotigotine for treatment or prevention of dopaminergic neuron loss
DE102004014841B4 (de) * 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
EP1824495A2 (en) * 2004-12-03 2007-08-29 ProteoSys AG Finasteride, dutasteride and related compounds for preventing/treating neurologically-associated disorders
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
ATE556712T1 (de) * 2005-06-07 2012-05-15 Kyowa Hakko Kirin Co Ltd A2a antagonisten zur behandlung von motorischen störungen
US9066903B2 (en) * 2006-02-28 2015-06-30 The United States Of America As Represented By The Department Of Veterans Affairs Pharmacological treatment of Parkinson's disease
US8802002B2 (en) 2006-12-28 2014-08-12 3M Innovative Properties Company Dimensionally stable bonded nonwoven fibrous webs
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938
US20090118376A1 (en) * 2007-11-02 2009-05-07 Ru-Band Lu Memantine Protects Inflammation-Related Degeneration of Dopamine Neurons Through Inhibition of Over-Activated Microglia and Release of Neurotrophic Factors from Astroglia
ES2538130T3 (es) 2008-06-12 2015-06-17 Amygdala Pty Ltd Detección de estados hipocinéticos y/o hipercinéticos
US20120053182A1 (en) * 2009-01-20 2012-03-01 Schering Corporation Methods of alleviating or treating signs and/or symptoms associated with moderate to severe parkinson's disease
TWI548411B (zh) * 2009-04-28 2016-09-11 Kyowa Hakko Kirin Co Ltd Exercise disorder treatment
KR101949754B1 (ko) * 2010-10-05 2019-02-19 제이엔씨 주식회사 적층 부직포와 그 제품
WO2012060844A1 (en) * 2010-11-05 2012-05-10 Biotie Therapies, Inc A2a antagonists as cognition and motor function enhancers
HK1201741A1 (en) * 2012-06-05 2015-09-11 International Stem Cell Corporation Method of prevention of neurological diseases
US9012640B2 (en) * 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
WO2014131090A1 (en) 2013-03-01 2014-09-04 Global Kinetics Corporation Pty Ltd System and method for assessing impulse control disorder
US10040817B2 (en) * 2013-10-03 2018-08-07 Enterin Laboratories, Inc. Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same
JP6381883B2 (ja) * 2013-10-04 2018-08-29 国立大学法人千葉大学 不随意運動の予防及び／又は治療組成物
EP3113684B1 (en) 2014-03-03 2020-07-01 Global Kinetics Pty Ltd System for assessing motion symptoms
WO2016148260A1 (ja) * 2015-03-17 2016-09-22 協和発酵キリン株式会社 医薬組成物
JP2018517785A (ja) 2015-06-19 2018-07-05 バイオティー セラピーズ インコーポレイテッド 制御放出トザデナント製剤
CN109414417A (zh) * 2016-03-17 2019-03-01 约翰·霍普金斯大学 通过paris的法尼基化预防或治疗帕金森症的方法
WO2017173067A1 (en) 2016-03-31 2017-10-05 Versi Group, Llc Delta opioid agonist, mu opioid antagonist compositions and methods for treating parkinson's disease
US11246871B2 (en) 2016-07-15 2022-02-15 Northwestern University Targeting adenosine A2A receptors for the treatment of levodopa-induced dyskinesias
JPWO2020189781A1 (ja) 2019-03-21 2021-06-03 協和キリン株式会社 パーキンソン病治療剤
EP3714888A1 (en) * 2019-03-25 2020-09-30 Assistance Publique - Hôpitaux De Paris Compounds for use in the treatment of adcy5-related dyskinesia
US10758535B1 (en) * 2019-04-26 2020-09-01 Sumitomo Dainippon Pharma Co., Ltd. Therapeutic drug for dyskinesia
JP7382737B2 (ja) * 2019-05-13 2023-11-17 東和薬品株式会社 イストラデフィリン製剤
CA3170917A1 (en) * 2020-03-10 2021-09-16 Mark Williams Purine compounds for treating disorders
WO2022167778A1 (en) 2021-02-02 2022-08-11 Haiku Therapeutics Ltd Ebselen as adenosine receptor modulator
US20250195457A1 (en) 2022-04-27 2025-06-19 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treatment of parkinson's disease

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992006976A1 (en) 1990-10-18 1992-04-30 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivative
US5484920A (en) * 1992-04-08 1996-01-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for Parkinson's disease
JP2928386B2 (ja) 1992-07-08 1999-08-03 協和醗酵工業株式会社 うつ病治療剤
WO1995003806A1 (en) 1993-07-27 1995-02-09 Kyowa Hakko Kogyo Co., Ltd. Remedy for parkinson's disease
EP0698607B1 (en) 1994-02-23 2002-05-29 Kyowa Hakko Kogyo Kabushiki Kaisha Xanthine derivative
AU743910B2 (en) 1997-03-24 2002-02-07 Kyowa Hakko Kirin Co., Ltd. {1,2,4}triazolo{1,5-c}pyrimidine derivatives
WO1999012546A1 (en) 1997-09-05 1999-03-18 Kyowa Hakko Kogyo Co., Ltd. Remedial agent for neural degeneration
WO1999026627A1 (en) * 1997-11-26 1999-06-03 Cerebrus Limited (-)-mefloquine to block purinergic receptors and to treat movement or neurodegenerative disorders
US6579868B1 (en) 1998-01-05 2003-06-17 Eisai Co., Ltd. Purine derivatives and adenosine A2 receptor antagonists serving as preventives/remedies for diabetes
AU2639299A (en) 1998-02-24 1999-09-15 Kyowa Hakko Kogyo Co. Ltd. Remedies/preventives for parkinson's disease
GB9819384D0 (en) * 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds II
GB9819382D0 (en) 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds I
DE69923197T2 (de) 1998-09-22 2005-12-29 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-DERIVATE
EP1177797A1 (en) 1999-05-12 2002-02-06 Fujisawa Pharmaceutical Co., Ltd. Novel use
GB9915437D0 (en) * 1999-07-01 1999-09-01 Cerebrus Ltd Chemical compounds III
NZ516260A (en) 1999-07-02 2004-08-27 Eisai Co Ltd Fused imidazole compounds and remedies for diabetes mellitus
FR2796759B1 (fr) 1999-07-23 2001-11-02 Gemplus Card Int Minicarte a circuit integre et procede pour son obtention
US6355653B1 (en) 1999-09-06 2002-03-12 Hoffmann-La Roche Inc. Amino-triazolopyridine derivatives
AUPQ441499A0 (en) 1999-12-02 2000-01-06 Fujisawa Pharmaceutical Co., Ltd. Novel compound
WO2001062233A2 (en) 2000-02-25 2001-08-30 F. Hoffmann La Roche Ag Adenosine receptor modulators
JP4128360B2 (ja) 2000-04-26 2008-07-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 排便を促進する医薬組成物
WO2001092264A1 (en) 2000-05-26 2001-12-06 Schering Corporation Adenosine a2a receptor antagonists
EP1797878A3 (en) 2000-06-21 2010-01-20 F. Hoffmann-La Roche AG Benzothiazole derivatives
ATE444752T1 (de) 2000-08-11 2009-10-15 Eisai R&D Man Co Ltd 2-aminopyridin-verbindungen und ihre verwendung als medikamente
GB0100620D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical cokpounds V
MXPA03009185A (es) * 2001-04-09 2004-02-17 Neurosearch As Antagonistas de receptor a2a de adenosina combinados con compuestos de actividad neurotrofica en el tratamiento de la enfermedad de parkinson.
ES2716404T3 (es) * 2002-01-28 2019-06-12 Kyowa Hakko Kogyo Kk Antagonistas de receptores A2A para su uso en el tratamiento de trastornos del movimiento
EA008339B1 (ru) * 2002-08-30 2007-04-27 Киова Хакко Когио Ко., Лтд. Способы лечения пациентов, страдающих синдромом усталых ног или связанными с ним заболеваниями
EA200501924A1 (ru) * 2003-06-10 2006-06-30 Киова Хакко Когио Ко., Лтд. Способ лечения тревожного расстройства
TW200507850A (en) * 2003-07-25 2005-03-01 Kyowa Hakko Kogyo Kk Pharmaceutical composition
US9238003B2 (en) * 2005-02-04 2016-01-19 Auburn University Extended or continuous wear silicone hydrogel contact lenses for the extended release of comfort molecules

Also Published As

Publication number Publication date
TR201903603T4 (tr) 2019-04-22
EP1469855A2 (en) 2004-10-27
KR20110010829A (ko) 2011-02-07
US20180221377A1 (en) 2018-08-09
JP4376630B2 (ja) 2009-12-02
CA2473864C (en) 2013-06-11
CO5601022A2 (es) 2006-01-31
US20060178379A1 (en) 2006-08-10
JP2005523898A (ja) 2005-08-11
CN101543497A (zh) 2009-09-30
AU2008200611B2 (en) 2011-12-15
EP2260850B1 (en) 2018-07-04
EP2044940A2 (en) 2009-04-08
EP2942082B1 (en) 2019-03-06
CA2813048A1 (en) 2003-08-07
KR20040077763A (ko) 2004-09-06
EA200400982A1 (ru) 2004-12-30
KR20120103740A (ko) 2012-09-19
PT2942082T (pt) 2019-06-06
EP2942082A2 (en) 2015-11-11
EP2260850A2 (en) 2010-12-15
US20060148827A1 (en) 2006-07-06
AU2008200611A1 (en) 2008-03-06
EP2942082A3 (en) 2016-01-27
WO2003063876A2 (en) 2003-08-07
KR101098209B1 (ko) 2011-12-23
WO2003063876A3 (en) 2003-11-27
KR20100056569A (ko) 2010-05-27
US7727993B2 (en) 2010-06-01
KR101166000B1 (ko) 2012-07-16
CN1646132A (zh) 2005-07-27
AU2003207734C1 (en) 2009-10-08
ES2686123T3 (es) 2018-10-16
US20040198753A1 (en) 2004-10-07
MXPA04007299A (es) 2004-10-29
CN101822676A (zh) 2010-09-08
HUE043353T2 (hu) 2019-08-28
US20170196872A1 (en) 2017-07-13
HUE039348T2 (hu) 2018-12-28
JP5612016B2 (ja) 2014-10-22
KR20150080013A (ko) 2015-07-08
EP2260850A3 (en) 2013-11-13
US20140249166A1 (en) 2014-09-04
JP5171556B2 (ja) 2013-03-27
JP2009067807A (ja) 2009-04-02
JP2012140461A (ja) 2012-07-26
AU2003207734B2 (en) 2008-02-21
US20120122897A1 (en) 2012-05-17
CA2473864A1 (en) 2003-08-07
BR0306919A (pt) 2004-11-09
ES2716404T3 (es) 2019-06-12
US7727994B2 (en) 2010-06-01
EP2044940A3 (en) 2010-11-10

Similar Documents

Publication Publication Date Title
HUE039348T2 (hu) A2A receptor antagonisták mozgási rendellenességek kezelésében történõ alkalmazásra
PL375053A1 (en) Sphingosine-1-phosphate receptor agonists in the treatment of demyelinating disorders
EP1755591A4 (en) OPHTHALMIC FORMULATIONS COMPRISING SELECTIVE ANTAGONISTS OF ALPHA RECEPTORS 1
AU2003286567A8 (en) Methods for the treatment of skin disorders
AU2003285091A8 (en) Interferon antagonists useful for the treatment of interferon related diseases
AU2003226927A8 (en) Novel carboxamide compounds for use in mch receptor related disorders
AU2003287880A8 (en) Cyclic quinoline compounds for use in mch receptor related disorders
HUS2200036I1 (hu) Dihidroimidazolonok alkalmazása kutyák kezelésére
IL183656A0 (en) Indenyl derivatives and use thereof for the treatment of neurological disorders
IL164697A0 (en) N-acyl piperidine derivatives for use as melanocortin receptor ligands in the treatment of feeding disorders
PL369822A1 (en) Use of endothelin receptor antagonists in the treatment of tumour diseases
IL157145A0 (en) Use of dc23 antagonists for the treatment of neoplastic disorders
AU2003290059A8 (en) Use of cd137 antagonists for the treatment of tumors
ZA200802552B (en) Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
AU2003267088A8 (en) Chemokine receptor antagonists as therapeutic agents
ZA200803236B (en) Adenosine A2a receptor antagonists for the treatment of Extra-Pyramidal syndrome and other movement disorders
AU2003236649A8 (en) Egf receptor antagonists in the treatment of gastric cancer
IL173746A0 (en) Modified il-4 mutein receptor antagonists
GB0219660D0 (en) Therapeutic use
PL370221A1 (en) 2-oxazolamines and their use as 5-ht2b receptor antagonists
AU2003250831A8 (en) Use of hec1 antagonists in the treatment of proliferative disorders and cancer
TWI365187B (en) 7-azaindoles and the use thereof as therapeutic agents
AU2003264297A1 (en) Use of vanilloid receptor antagonists for the treatment of pain
EP1812009A4 (en) GABA-STEROID ANTAGONISTS AND THEIR USE FOR THE TREATMENT OF DISEASES OF THE CNS
AU2003259759A1 (en) Gal3 receptor antagonists for the treatment of affective disorders